

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 April 2008 (24.04.2008)

PCT

(10) International Publication Number
WO 2008/048996 A2

(51) International Patent Classification:

A01N 57/00 (2006.01)

(21) International Application Number:

PCT/US2007/081621

(22) International Filing Date: 17 October 2007 (17.10.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/852,263 17 October 2006 (17.10.2006) US

60/875,736 19 December 2006 (19.12.2006) US

(71) Applicant (for all designated States except US): **DYAX CORP.** [US/US]; 300 Technology Square, 8th Floor, Cambridge, Massachusetts 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JAIN, Rakesh K.** [US/US]; 65 East India Row #14B, Boston, Massachusetts 02110 (US). **WOOD, Clive R.** [US/US]; 2 Hawthorne Place, Apt. 17R, Boston, Massachusetts 02114 (US).

DRANSFIELD, Daniel T. [US/US]; 14 George Street, Hanson, Massachusetts 02341 (US). **ARULANANDAM, Antonio** [US/US]; 4 Skyline Drive, Winchester, Massachusetts 01890 (US).


(74) Agent: **LAWRENCE, Laurie, Butler;** Lowrie, Lando & Anastasi, LLP, One Main Street, Eleventh Floor, Cambridge, MA 02142 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: SEQUENTIAL COMBINATION THERAPY



▲ Control IgG 20mg/kg Q2D (Day1) + Bevacizumab 10mg/kg Q3D (Day10)

△ DX-2240 20mg/kg Q2D (Day1) + Bevacizumab 10mg/kg Q3D (Day10)

● Control IgG 20mg/kg Q2D (Day1) + Bevacizumab 10mg/kg Q3D (Day20)

○ DX-2240 20mg/kg Q2D (Day1) + Bevacizumab 10mg/kg Q3D (Day20)

(57) Abstract: Disclosed are new methods for treatment of angiogenesis-related disorders. Angiogenesis-related disorders are treated by administration of a Tie1 ectodomain-binding agent and a VEGF antagonist agent.



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*